Allogeneic stem cell transplantation (SCT) is an effective treatment for patients with leukemia since it causes an immune-mediated elimination of residual leukemic cells, termed graft-versus-host (GVL) reactivity. 1, 2 Unfortunately, the occurrence of graft-versus-host disease (GVHD) is a frequent and life-threatening complication.
1,2 T cellmediated immunity is clearly involved in both the graftversus-host (GVH) and GVL response since T cell depletion of the allogeneic stem cell graft effectively reduces the occurrence of GVHD, but also results in an increased risk of recurrent leukemia. 2 Moreover, infusion of T cells from the original stem cell donor to patients with leukemic relapse after allogeneic stem cell transplantation (SCT) induces complete remissions in the majority of patients with chronic myeloid leukemia (CML) and in about 30% of patients with acute myeloid leukemia (AML). 3 However, most of the responding patients develop life-threatening GVHD.
Antigen recognition by T cells is mediated by the T cell receptor (TCR) that exists in two basic heterodimeric forms, the ␣␤ and ␥␦ TCR. TCR␣␤ cytotoxic T lymphocytes (CTL) recognizing peptide antigens presented by MHC molecules on host leukemic cells have been isolated from SCT recipients and HLA-identical stem cell donors. Some of these TCR␣␤ CTL clones recognize antigens selectively expressed by leukemic cells that may induce only GVL reactivity against the tumor without affecting the normal cells of the host leading to GVHD. [4] [5] [6] [7] In addition, non-MHC-restricted TCR␥␦ CTL recognizing non-peptide ligands have also been shown to exert specific lysis of tumor cells. [8] [9] [10] [11] It has been shown that the selective lysis of tumor cells by TCR␥␦ CTL is regulated by killer cellinhibitory receptors (KIRs) expressed at their cell surface. 12 These KIRs are a family of Ig-like molecules specifically binding to polymorphic determinants of MHC class I molecules. KIRs with two Ig domains bind to HLA-C allotypes. The KIR p58.1 (CD158a) recognizes an epitope shared by group 1 HLA-C allotypes (Cw2, 4, 5 and 6), whereas p58.2 (CD158b) recognizes a shared epitope of group 2 HLA-C allotypes (Cw1, 3, 7 and 8) . A KIR with three Ig domains, p70, recognizes an epitope shared by HLA-Bw alleles and a homodimer of receptors with three Ig domains, p140, recognizes HLA-A3 and HLA-A11. 13 The interaction between these KIRs on CTL and the appropriate MHC class I allotype on potential target cells inhibits TCR-mediated functions including cytotoxic activity and lymphokine production. [14] [15] [16] [17] [18] [19] In our search for cytotoxic effector cells that selectively recognize leukemic but not normal cells, we have investigated the specificity of T cell cultures generated from PBL of SCT recipients after in vitro stimulation with leukemic cells. Here, we report that a TCR␥␦ CTL clone expressing the p58.2 KIR kills AML cells very efficiently, but does not kill PHA-stimulated T cells and EBV-transformed B cells from the same patients. We show that protection of non-malignant hematopoietic cells from lysis by this TCR␥␦ CTL is mediated by p58.2 which specifically binds to group 2 HLA-C allotypes. We found that AML cells and AML cell lines express a much lower level of MHC class I molecules when compared to non-malignant cells and are, therefore, susceptible to lysis by p58.2 + TCR␥␦ CTL.
Material and methods

Antibodies and immunofluorescence analysis
The following MoAb were used for immunofluorescence analysis, for cell sorting or for inhibition of cytotoxicity: /ml) with irradiated leukemia cells from the patient (10 6 /ml) in IMDM (Gibco BRL, Paisley, UK) supplemented with 10% pooled human serum. On day 7 and day 14, T cell cultures were restimulated with irradiated leukemia cells from the patient (10 6 /ml) and 100 U/ml IL-2 (Glaxo, Geneva, Switzerland) was added. From day 21 on, TCR␥␦ CTL cultures were expanded by weekly restimulation with an irradiated EBV-transformed lymphoblastoid cell line (EBV-LCL) of the patient pre-SCT (10 6 /ml), irradiated Daudi cells (10 5 /ml), and 100 U/ml IL-2. p58.2 expressing NK cells were isolated by flow cytometry using MoAb GL183 and CD56. CD56
+ NK cells were expanded by stimulation with irradiated allogeneic PBL, EBV-LCL JY, 1 g/ml PHA and 100 U/ml IL-2. After 14 days, NK cell cultures were used in cytotoxicity assays.
Target cells
Tumor cells were collected from AML patients at diagnosis. Cell lines Lama and Kasumi were derived from patients with AML. 20, 21 The stable transfectants 721.221.Cw*0304 and 721.221.Cw*0401 were kindly provided by Dr V Braud (Institute of Molecular Medicine, John Radcliff Hospital, Oxford, UK). EBV-LCL were generated from PBMC by transformation with EBV of the EBV-shedding B95-8 cell line and 0.1 g/ml CsA. All cell lines were cultured in IMDM supplemented with 10% FCS. T cell blasts were generated by stimulating PBMC with 4 g/ml PHA in IMDM plus 10% pooled human serum for 3 days. T cell blasts were washed and further cultured with 100 U/ml IL-2 for 3 days.
Chromium release assay
Specific lysis was determined by chromium release assays. Briefly, 10 6 target cells were incubated with 100 Ci 51 Cr (Amersham, Buckinghamshire, UK) for 1 h. Labeled target cells were mixed in V-bottom microtiter plates (10 3 /well) with various numbers of effector cells in 150 l IMDM with 10% FCS. After 4 h of incubation at 37°C, 100 l supernatant of each sample was collected and radioactivity was determined by a gamma counter.
HLA-Cw subtyping
HLA-Cw typing was performed by PCR using sequencespecific primers (PCR-SSP). Primers were designed according to Bunce et al 22 and extended with additional primers to increase the resolution. The PCR was modified to run under the conditions of the 12th IHW protocols for class I ARMS-PCR. The Cw*0707 and Cw*0709 alleles which possess the sequence for the Asn77, Lys80 p58 KIR motif are not detected by the primers specific for Cw*07 allotypes. The Cw*1507 allele containing the sequence for the Ser77, Asn80 p58 KIR motif is not detected by the primers specific for Cw*15 allotypes.
Results
Isolation and characterization of a TCR␥␦ CTL selectively recognizing AML
To examine whether CTL with selective anti-leukemic reactivity are present within the T cell repertoire of SCT recipients, we tested cytotoxic activity of T cell cultures generated from PBL by stimulation with irradiated leukemic cells of the patient. One of the T cell cultures obtained showed significant cytotoxicity against the patient's AML cells (49% specific lysis; E:T ratio 10:1). Phenotypic analysis of this bulk culture revealed that 40% of the cells expressed the ␥␦ TCR, whereas the other 60% of the cells were CD4 Inhibition of cytotoxicity against AML cells of patient VE. Blocking studies were performed using purified MoAb (10 g/ml) which was present throughout the assay. The effector:target cell ratio was 10:1.
CD2, CD3 and TCR␥␦, but does not express TCR␣␤, CD4 and CD8 (data not shown). Next, we tested the capacity of TCR␥␦ CTL VE to recognize freshly isolated leukemic cells and cell lines derived from AML patients. We observed that AML cells obtained from patient VE at diagnosis were very efficiently lysed by the CTL (Figure 1a) . Moreover, AML cells isolated from two other patients and the AML cell lines Lama and Kasumi were also efficiently killed by CTL VE (Figure 1a ). Lysis of AML cells was inhibited by anti-CD3 and anti-TCR␥␦ MoAb, but MoAb directed against CD4, CD8, HLA class I and HLA class II were ineffective (Figure 1b ). These data indicate that CTL VE recognizes its target ligand through the TCR␥␦CD3 complex which results in strong cytolytic activity against freshly isolated myeloid leukemia cells and leukemic cell lines. The ␥␦ TCR of CTL VE is composed of V␥9 and V␦1 chains, as determined by staining with MoAb specific for these TCR V gene segments (data not shown). In the peripheral blood of healthy individuals the dominant TCR␥␦ + subset co-expresses V␥9 and V␦2 chains, and this population constitutes 70-90% of all TCR␥␦ + T cells. 23 The 
Selective inhibition of cytotoxic activity of TCR␥␦ CTL VE
To investigate whether TCR␥␦ CTL VE selectively recognizes leukemia cells, we compared its anti-leukemic reactivity with cytolytic activity mediated against HLAmatched PHA-stimulated T cells and EBV-transformed B cells derived from the AML patients. Interestingly, TCR␥␦ CTL VE did not lyse these non-malignant hematopoietic Bone Marrow Transplantation cells (Figure 2) . Recently, it has been shown that TCR␥␦ CTL express KIRs that regulate the cytotoxic effector function of these cells. Therefore, we analyzed CTL VE for expression of MHC class I-specific KIRs. CTL VE expressed p58.2, but p58.1 and p70 were not present ( Figure 3 ). The p58.2 receptor binds to HLA-C allotypes that have Ser and Asn residues at positions 77 and 80 (ie group 2 HLA-C allotypes). 12 HLA-C allelic typing of the AML patients and cell lines revealed that they all were positive for at least one HLA-C subtype with a Ser at position 77 and an Asn at position 80 (Table 1) . High expression of these HLA-C subtypes at the cell surface of target cells may result in inhibition of cytotoxicity upon binding with p58.2. Therefore, we determined the level of expression of MHC class I molecules on AML cells and cell lines as well as on non-malignant target cells ( Table  2) . The results clearly show that freshly isolated AML cells have a significantly lower expression of MHC class I molecules when compared to PHA-stimulated T cells or EBVtransformed B cells. The AML cell lines Lama and Kasumi almost completely lack MHC class I expression. These results suggest that TCR␥␦ CTL VE exerts strong cytolytic activity against AML cells by lack of inhibition due to low expression of group 2 HLA-C molecules, whereas non- a HLA-Cw typing was performed by PCR using sequence-specific primers, as described in Materials and methods. The Cw*0707 and Cw*0709 allotypes which possess the sequence for the Asn77, Lys80 p58 KIR motif are not detected by the primers specific for Cw*07 allotypes. The Cw* 1507 allotype containing the sequence for the Ser77, Asn80 p58 KIR motif is not detected by the primers specific for Cw*15 allotypes. All known Cw*08 allotypes possess the sequence for the Ser77, Asn80 p58 KIR motif.
malignant hematopoietic cells are protected from lysis due to high expression. To determine whether AML cells are generally more susceptible to non-MHC-restricted lysis than non-malignant hematopoietic cells, we tested these cells for lysis by two p58.2-expressing NK cell lines generated from PBL of two healthy donors (donor HD and FM). NK cell lines generated from both donors are CD3
+ , and express p58.2 KIR but do not express p58.1 and p70 (data not shown). NK cell line HD efficiently kills the MHC class I-negative AML cell lines Lama and Kasumi, and exerts significant lysis of freshly isolated AML cells but not of PHA-stimulated T cells generated from the same patients (Figure 4 ). This reactivity pattern is similar to that displayed by the TCR␥␦ CTL VE. NK cell line FM also efficiently kills the MHC class I-negative AML cell lines Lama and Kasumi, but freshly isolated AML cells are resistant to lysis by this NK cell line ( Figure 4 ). As shown in Table 2 , freshly isolated AML cells of patients VH and HB do not completely lack expression of all MHC class I alleles, in contrast to the AML cell lines Lama and Kasumi which are almost completely MHC class I negative. Therefore, the presence of inhibitory receptors other than p58.2 may be responsible for the partial or complete inhibition of Table 2 Cell surface expression of MHC class I by the different target cells
Patient
Cell VE  AML  119  52  0  132  PHA T blasts  340  114  0  325  EBV-LCL  370  144  0  322   VH  AML  53  0  12  42  PHA T blasts  361  0  188  343  EBV-LCL  289  0  156  185   HB  AML  119  22  0  50  PHA T blasts  414  114  0  334  EBV-LCL  327  102  0  273   Lama  AML  10 
Inhibition of cytolytic activity of TCR␥␦ CTL VE by p58.2 engagement
Next, we studied the involvement of p58.2 in inhibition of lysis by TCR␥␦ CTL VE in more detail. First, we tested the effect of anti-HLA-B/C MoAb on the lysis of nonmalignant hematopoietic cells. Addition of this antibody during the chromium release assay significantly restored lysis of PHA-stimulated T cells (Figure 5a ). Secondly, CTL VE significantly lysed the MHC class I-negative cell line 721.221 either non-transfected or stably transfected with the HLA-Cw*0401 allotype (Asn77, Lys80 motif), whereas HLA-Cw*0304-transfected 721.221 cells (Ser77, Asn80 motif) are resistant to lysis (Figure 5b) . Finally, we determined whether triggering of p58.2 influences TCR/CD3-directed killing by CTL VE. Binding of anti-CD3 or anti-TCR␥␦ MoAb to Fc␥ receptors on P815 cells induces killing of these target cells by CTL VE (Figure 6 ). Anti-p58.2 MoAb bound to the Fc␥ receptors of P815 target cells inhibits both CD3 and TCR␥␦ MoAb-directed killing, whereas anti-p58.1 MoAb has no effect ( Figure 6 ). These 
Discussion
CTL reactivity is thought to be important in the elimination of residual leukemic cells after allogeneic SCT. Unfortunately, the occurrence of life-threatening GVHD is strongly associated with this anti-leukemic CTL reactivity. TCR␣␤ CTL have been isolated from the peripheral blood of SCT recipients that recognize antigens selectively expressed by leukemic cells. [4] [5] [6] [7] Such leukemia-reactive CTL can exert specific anti-leukemic cytotoxicity while they do not attack normal cells and lead to GVHD. The present report describes a leukemia-specific CTL expressing a V␥9/V␦1 TCR. This CTL clone efficiently kills AML cells, whereas HLA-matched PHA-stimulated T cells and EBV-transformed B cells generated from the same leukemia patients are not lysed. We revealed that the leukemia-restricted cytotoxicity displayed by this TCR␥␦ CTL is regulated by the p58.2 KIR. Engagement of p58.2 results in an inhibitory signal that predominates over TCR␥␦CD3 complexmediated activation of the CTL. Therefore, PHA-stimulated T cells and EBV-transformed B cells that express high lev- els of group 2 HLA-C molecules trigger the p58.2 receptor resulting in inhibition of lysis, whereas low levels of HLA-C molecules as expressed on AML cells do not. Consequently, AML cells are very efficiently lysed by the p58.2 + TCR␥␦ CTL. These findings indicate that cytolytic activity of TCR␥␦ + T cells recognizing broadly distributed antigens can be controlled by the cell surface expression of KIRs, which confirm and extend results of other investigators. [17] [18] [19] Tumor cell lysis by either TCR␥␦ + T cells and NK cells is clearly dependent on decreased levels of MHC class I molecules on tumor cells. 24, 25 Lack or down-regulation of MHC class I expression on leukemic cells has been reported. 26 We observed that the level of MHC class I expression of freshly isolated AML cells and AML cell lines was much lower than the expression on PHA-stimulated T cells and EBV-transformed B cells. This can result in the loss of protection from non-MHC-restricted lysis by TCR␥␦ + T cells and NK cells. We showed that AML cells and AML cell lines are susceptible to non-MHC-restricted lysis by p58.2 + TCR␥␦ CTL as well as p58.2 + NK cells. Albi et al 27 have reported that an increased number of p58.2 + TCR␣␤ + CD8 + T cells displaying non-MHC-restricted lysis in vitro was detected in SCT recipients of HLAmismatched bone marrow. These KIR expressing TCR␣␤ + T cells lysed patients' leukemic cells, whereas non-malignant cells were protected from lysis. Also, it has been reported that p58.2 (CD158b) + T cells increase after HLAmatched allogeneic SCT. 28 Cambiagi et al 29 showed that transgenic expression of the CD158b KIR prevents in vivo rejection of an H-2-mismatched mice bone marrow graft. Together, these data suggest that CD158b + T cells and NK cells displaying non-MHC-restricted lysis may have some role in selective anti-leukemic reactivity following SCT, while normal cells are protected from lysis thereby reducing GVHD.
Leukemic relapse after allogeneic SCT is a serious problem. A strategy to augment GVL reactivity without causing GVHD may be to generate CTL with specific anti-leukemic reactivity from allogeneic donors in vitro and adoptively transfer these CTL to BMT recipients with relapsed leukemia. Such CTL directed against leukemia-specific antigens will not exert GVHD. Alternatively, CTL recognizing antigens with a broad tissue distribution and that express KIRs may also selectively exert GVL reactivity. The expression of KIRs on in vitro generated anti-leukemic CTL may be induced by certain cytokines or by transferring KIR genes into CTL employing retroviral vectors that can safely be administered to SCT recipients with relapse. [30] [31] [32] 
